Issue link: http://osercommunicationsgroup.uberflip.com/i/265900
C h a i n D r u g s t o r e D a i l y 6 9 Tu e s d a y, A u g u s t 1 3 , 2 0 1 3 health and beauty care products includ- ing: Nutra Nail nail treatments and Gel Perfect nail color, Plus White whitening gels and toothpastes, Sudden Change anti-aging skin care treatments, Mega-T diet supplements, Bikini Zone & Hair Off hair removal treatments and depilato- ries, Scar Zone scar treatments and Solar Sense sun care products. CDD: What was the most significant event or series of events affecting your company in the past year? SH: Nutra Nail Gel Perfect Color Brand is one of the best selling new nail lines right now. It's a patented formula featur- ing a polymerization action in which gel color and an activator work together to bond on finger or toenails to set rock solid in five minutes to a brilliant shine without any UV/LED lights. In just five minutes, you can put your toes in shoes or hands in your purse and be out the door. The quick drying power makes pedicures easy and painless as well, mak- ing it convenient for women to give themselves pedicures year round. Also, our patent pending No Mess Express pol- ish remover will remove regular polish in seconds and Gel Perfect in as little as two minutes. The whole process is quick and easy for at-home use. CDD: Are you introducing any new products? SH: We are introducing 15 totally new products for 2014 in six major product categories. 2014 will be our largest launch year yet! We are launching a totally new line of nail color called Nutra Nail Amplify, to compliment our Nutra Nail Gel Perfect color line. Amplify provides a unique lacquer color with a synergistic amplifier all in one package. Amplify delivers extended wear, intensified color, and magnified shine – the look and shine women want! CCA Industries (Cont'd. from p. 1) We have an entire new line of Value Sized Mega-T dietary supplements that deliver optimum value to consumers and retailers alike. We also have several new innovative diet items, including Mega T Chews, a great new appetite suppressant that tastes great! In skin care, CCA is introducing all new Sudden Change Under Eye Gel, a Youth Recovery Serum and a Youth Recovery Complete System, focused on delivering a younger look at a terrific value. In scar treatments, we have a new Scar Zone Advanced, offering a supe- rior formula that allows for once per day application and 24 hour mois- ture/protection. In oral care, we are introducing new Plus White Plus toothpaste and Plus White Whitening Pen, delivering superior whitening and protection at a great value! In sun care, the entire Solar Sense line is completely monograph compliant, with each sku containing a superior 14.5 percent level of Zinc sunscreen, as well as introducing two new sku's for 2014. CDD: What distinguishes your prod- uct(s) from the competition? SH: We offer unique innovative products that are incremental and profitable to the retail categories where we compete. We also offer a wide variety of displays and will work with retailers when needed so we can to help define which ones work for their stores. CDD: To what do you attribute your company's success? SH: CCA continues to launch innovative products in the beauty-care categories and continues to advertise these products with great TV, print,and social media campaigns as well as public relations that create consumer demand. For more information, visit booth 5055 or go online to www.ccaindustries.com. having launched more AGs with brand pharmaceutical partners than any other company. In addition to authorized generics, we continue to expand our capabilities. The future of Prasco lever- ages more than 40 years of experience in the pharmaceutical market and will take partnering to a whole new level. Our comprehensive pharmaceutical infra- structure has a proven history of per- formance and leadership and is capable of launching products in a multitude of unique market situations. CDD: Are authorized generics gaining in demand in the pharma marketplace? CA: With the increasing number of prod- ucts available as generics today, and the substitution rate continuing to rise, we are seeing an uptake in demand and con- sumer awareness of authorized generics. This is due in part to high profile con- sumer media attention and features such as the recent Dr. Oz segment on the ben- efits of Authorized Generics. Along with providing additional generic choices, the presence of Authorized Generics, espe- cially during the 180-day exclusivity period, creates significant opportunity for the pharmacies. AGs create competition in the marketplace. And when the com- petition created by an authorized generic combines with the growing availability of generic products the entire consuming marketplace wins. CDD: In addition to the authorized generic life cycle extension strategy, how is Prasco poised to deliver value to brand pharma? CA: We've established a high level of expectation with our partners. Our fully- customizable pharmaceutical infrastruc- ture allows us to access the market and Prasco Labs (Cont'd. from p. 1) launch products rapidly, efficiently, and effectively. No matter the size of the product or organization, our specialized lifecycle capabilities provide our partners with strategic insights and experience, that when combined with their existing assets, have proven to significantly enhance their business. This model can be utilized across any market scenario. We're seeing a significant trend in organ- izations that are requiring less infrastruc- ture, and we are focusing on partnering with Prasco for our unique approach and comprehensive expertise. CDD: How do you see Prasco character- ized five years from now? CA: Today's pharmaceutical company looks very different from one even ten years ago, where there were clear lines of distinction between brand and generic pharmaceutical companies. The future growth of Prasco will reside in our proven ability to access a multitude of unique market situations. Prasco will remain the leader in authorized gener- ics, continuing to stand for high quality products and superior service while continuing to expand our footprint in the pharmaceutical marketplace. For more than 40 years, we've strived to create opportunities and solutions that find and fill unmet needs in the pharma- ceutical marketplace. We've partnered with more than 35 of the top pharma- ceutical companies to represent more than 50 of their brands. In today's ever- changing marketplace, Prasco will expand its presence, anticipating cus- tomer needs and market dynamics of tomorrow providing high-quality prod- ucts and new revenue opportunities through creative partnerships. For more information, visit booth 2101 and 2103 at the NACDS Total Store Expo or go online to www.prasco.com. to market remains Camber's focus. With more than 50 ANDA's in various stages of review with the FDA, Camber's future plans include filing up to 20 ANDA's annually. The pipeline includes a wide range of therapeutic categories, such as antiretroviral, antiulcerant, antineoplas- tic, cardiovascular, antibacterial, antide- pressant, antidiabetic and more. With new product releases that include Escitalopram Tablets and Solution, Indomethacin ER, Irbesartan,Levocetirizine Camber Pharmaceuticals (Cont'd. from p. 1) and Zonisamide, Camber will remain one of the fastest growing generic companies in the United States for years to come. Located in Piscataway, N.J., Camber Pharmaceuticals is a fully integrated interna- tional pharmaceutical company that main- tains quality and integrity in all its products, from API manufacturing to finished dosage. For more information about Camber Pharmaceuticals, visit booth 4011 at the NACDS Total Store Expo, go online to www.camberpharma.com or call 732- 529-0430. the many ways Mallinckrodt demon- strates its commitment to being a leader in generic pharmaceuticals. Global Leader Mallinckrodt Generic Pharmaceuticals offers a comprehensive product portfolio with an industry-leading expertise in pain management. It is the largest U.S. suppli- er of opioid pain medications and among the top 12 generic pharmaceuticals man- ufacturers in the U.S., based on prescrip- tions (Source: IMS Health, Dataview, December 2012) Mallinckrodt is also one of the world's leading producers of bulk acetaminophen. 145 Years of Tradition and Growing Mallinckrodt recently launched several new generic products to the market, con- tinuing the history of expert manufactur- ing and product development that started when the Mallinckrodt brothers formed the first chemical manufacturing compa- ny west of the Mississippi. The Generic Pharmaceuticals business developed as a natural exten- sion of the company's acetaminophen raw materials business. Many of the generic products use the sifted aceta- minophen produced by Mallinckrodt's Active Pharmaceuticals Ingredients (API) business, which allows the com- pany to ensure a reliable source and quality of supply. Mallinckrodt saw potential in the generics business and decided to pursue manufacturing its own tablets. In 1996, the company pur- chased Graham Labs in Hobart, N.Y., to add Specialty Generics to its portfo- Mallinckrodt (Cont'd. from p. 1) lio of businesses. Investing in the Future The same goal of providing high quality, innovative products that began 145 years ago with the Mallinckrodt brothers con- tinues today. "Our company believes in the origi- nal values that built Mallinckrodt so many years ago — quality, service and integrity," said Mark Trudeau, President and Chief Executive Officer, Mallinckrodt Pharmaceuticals. "Recently launched as a standalone company, we're building on our tradition by invest- ing in our core strengths of manufactur- ing and development. We're committed to meeting customer needs for today while also creating a long-term growth strategy that will continue our tradition for many more generations." Mallinckrodt is investing in several infrastructure and capacity improve- ments to consistently deliver the high- quality products customers need. Expansion of the high-volume manufac- turing facility in Hobart will increase production of generic pharmaceuticals, and new packaging lines will improve product output. Investments also are being made within Mallinckrodt's API business to increase capacity and relia- bility of raw materials for generic phar- maceuticals. These investments throughout the Mallinckrodt pharma- ceuticals business will ensure a quality product is available to customers for years to come. For more information about Mallinckrodt, visit booth 2408 or go online to www.mallinckrodt.com.